MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study
Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study
Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study
Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study
Journal Article

Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study

2015
Request Book From Autostore and Choose the Collection Method
Overview
Purpose Evidence-based medicine promotes the current best evidence from clinical trials to guide decisions for individual patients. We assessed whether chronic obstructive pulmonary disease (COPD) patients included in exercise training studies and pharmacologic trials match those from a non-selected COPD target population sample. Methods Exercise training studies were identified in a literature search. Towards a Revolution in COPD Health (TORCH) and Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) were chosen to represent pharmacologic trials. Burden of Obstructive Lung Disease (BOLD) data were used to characterize target COPD population (BOLD target), defined as the presence of dyspnea (modified Medical Research Council ≥2) and non-reversible airway obstruction (post-bronchodilator FEV1/FVC ≤0.7 and FEV1% predicted ≤70 %). Results Overall 240 exercise training studies with 13,901, TORCH and UPLIFT with 12,105, and BOLD with 16,218 participants were evaluated. Males were overrepresented in exercise training studies (67.5 %) and pharmacologic trials (TORCH 75.8 %; UPLIFT 74.6 %), whereas in BOLD target 55.8 % were males ( p  < 0.001). In exercise training studies, 7.2 % were never-smokers, 0.0 % in TORCH and UPLIFT, but 36.0 % in BOLD target ( p  < 0.001). Subjects with cardiac comorbidity were excluded from 75.4 % of exercise training studies, entirely from TORCH and UPLIFT, but comprised 24.5 % of BOLD target. Conclusions COPD patients recruited in exercise training studies and in pharmacologic trials differ from target population of symptomatic COPD. Females, never-smokers, and patients with cardiac comorbidities are more likely excluded from the clinical trials.